1. Cannabinoid Receptors and Analgesia
======================================

Basic research indicates that endocannabinoids play a well-established role in alleviating behavioral responses to acute, inflammatory and neuropathic pain \[[@B1-pharmaceuticals-03-02661],[@B2-pharmaceuticals-03-02661],[@B3-pharmaceuticals-03-02661]\]. A large body of studies using receptor deletion and selective agonists and antagonists have suggested that analgesia is due to the activation of both cannabinoid subtype 1 and 2 (CB1 and CB2) receptors \[[@B4-pharmaceuticals-03-02661],[@B5-pharmaceuticals-03-02661],[@B6-pharmaceuticals-03-02661],[@B7-pharmaceuticals-03-02661]\]. The role of CB1 receptor in modulating pain is confirmed by its wide distribution within the key sites of pain neuraxis. CB1 receptors are densely expressed on the superficial layers of spinal dorsal horn, the dorsal root ganglia, the peripheral terminals of primary afferent neurons and within the pain descending pathway \[[@B8-pharmaceuticals-03-02661]\]. CB2 receptors are mainly located in the immune system therefore representing a target in inflammatory pain processing. Although early studies did not find CB2 receptors in the central nervous system, recent works have reported the presence of CB2 mRNA within the spinal cord \[[@B9-pharmaceuticals-03-02661]\] and CB2 receptor protein within the brain \[[@B10-pharmaceuticals-03-02661],[@B11-pharmaceuticals-03-02661]\]. Consequently CB2 expression within the brainstem, cortex and cerebellum has been confirmed at this point \[[@B11-pharmaceuticals-03-02661]\]. The functional role of CB2 receptors in the CNS is however still unclear since a functional imaging study has demonstrated that CB2 receptor antagonism did not modify brain activation evoked by systemic administration of a non-selective cannabinoid agonist \[[@B12-pharmaceuticals-03-02661]\] suggesting that CB2-mediated cannabinoid-induced changes in brain activity are not functionally active under normal physiological conditions.

The wide distribution of CB receptor within the main pain processing sites offers an unlimited potential for inducing analgesia in several pain conditions. Stimulation of spinal cord CB1 receptor has been shown to inhibit nociceptive responses in *in vivo* and *in vitro* studies \[[@B13-pharmaceuticals-03-02661],[@B14-pharmaceuticals-03-02661],[@B15-pharmaceuticals-03-02661],[@B16-pharmaceuticals-03-02661],[@B17-pharmaceuticals-03-02661],[@B18-pharmaceuticals-03-02661]\]. The contribution of peripheral CB1 receptors in analgesia has been assessed in a recent study in which CB1 receptors were selectively ablated in primary nociceptive sensory neurons with no change in CB1 receptors elsewhere, including the central nervous system. Resulting mice were phenotypically hypersensitive to noxious heat or mechanical stimuli and developed increased neuropathic pain by nerve injury. The same mice were unresponsive to locally or systemically administered cannabinoids, while they instead responded to those intrathecally administered \[[@B19-pharmaceuticals-03-02661]\].

Apart from CB1 and CB2 receptors, anandamide and other "endocannabinoids" such as *N*-arachidonoyl dopamine (NADA) activate the transient receptor potential vanilloid type 1 (TRPV1) channel \[[@B20-pharmaceuticals-03-02661],[@B21-pharmaceuticals-03-02661],[@B22-pharmaceuticals-03-02661]\]. TRPV1 is a non selective cation channel belonging to the large family of transient receptor potential (TRP) channels which is activated by noxious heat (\>42 °C), low pH (\>6.0) and by the red hot chilli pepper constituent capsaicin. Anandamide has been recently shown to excite C-fibers and to produce nociceptive behaviour via TRPV1 activation \[[@B23-pharmaceuticals-03-02661]\]. Moreover, prostaglandins and bradykinins increase TRPV1 sensitivity to anandamide under inflammatory conditions \[[@B24-pharmaceuticals-03-02661]\]. Transient receptor potential vanilloid type 4 (TRPV4) channel is also activated by anandamide and arachidonic acid metabolites produced from anandamide hydrolysis and CYP450 oxygenases \[[@B25-pharmaceuticals-03-02661],[@B26-pharmaceuticals-03-02661]\]. Its stimulation promotes the release of substance P and CGRP neuropeptides from central projections of primary afferents in the spinal cord \[[@B27-pharmaceuticals-03-02661]\]. Its role in detecting warm temperatures and in chemically induced thermal hyperalgesia has been confirmed by TRPV4^−/−^ mice which showed markedly reduced carrageenan and capsaicin-induced hyperalgesia \[[@B28-pharmaceuticals-03-02661]\]. Moreover, under certain conditions, such as inflammatory pain, functional interaction between transient receptor potential ankyrin type 1 (TRPA1) and TRPV1 channels leads to the integration of inflammation-induced stimuli by sensory neurons. Inflammation-induced activation of the TRPA1 channel is controlled by the TRPV1 channel and by diacylglycerol (DAG) and 2-AG, the effects of which are also greatly enhanced via functional interaction with TRPV1. Activation of TRPV1 and TRPA1 leads to desensitization and consequent behavioral analgesia. Cannabinoids and/or endocannabinoids gate, directly and indirectly, at least five TRP channels, although they seldom act as full agonists \[[@B29-pharmaceuticals-03-02661],[@B30-pharmaceuticals-03-02661]\] so that the TRP-mediated responses may not reach the threshold level to induce nociceptor excitation. By this subject these TRP channels are often referred as ionotropic cannabinoid receptors (ICR).

2. Cannabinoid Receptors and Supraspinal Pain Modulation
========================================================

Supraspinal sites of cannabinoid-induced antinociception were initially revealed by indirect studies in which the antinociceptive effects of Δ^9^-THC \[[@B16-pharmaceuticals-03-02661]\] or the effects of systemically administered cannabinoids on noxious stimulus*-*evoked responses \[[@B31-pharmaceuticals-03-02661]\] were preserved following spinal transections. Direct evidence of supraspinal sites of cannabinoid analgesic action has been provided by the observation that intraventricular administration of cannabinoid agonists, such as WIN55212-2, CP55940 and Δ^9^*-*THC, induced antinociception \[[@B32-pharmaceuticals-03-02661],[@B33-pharmaceuticals-03-02661]\]. The identification of supraspinal sites of cannabinoid-induced antinociception has been made possible by site-specific injections of cannabinoid agonists to various brainstem areas. Microinjections of cannabinoids into sites such as the dorsolateral periaqueductal grey (PAG), dorsal raphe nucleus (DRN), rostral ventromedial medulla (RVM), amygdala, lateral posterior and submedius regions of the thalamus, superior colliculus, and noradrenergic A5 region have been shown to produce antinociceptive effects \[[@B34-pharmaceuticals-03-02661],[@B35-pharmaceuticals-03-02661],[@B36-pharmaceuticals-03-02661],[@B37-pharmaceuticals-03-02661]\].

3. Cannabinoid Receptors in Pain Descending Pathway
===================================================

The descending nociceptive modulatory system represents an endogenous antinociceptive system, whose electrical or chemical activation counteracts pain. Its discovery dates back to 1969 when Reynolds \[[@B38-pharmaceuticals-03-02661]\] observed that PAG electrical stimulation produces strong analgesia in rats. It is now well established that this brainstem*-*spinal pathway inhibits pain (for comprehensive reviews see 39-41). A potential treatment for silencing pain is therefore the activation of the PAG-RVM-dorsal horn (DH) circuitry, which is the best characterized pain modulation system through which pain is endogenously inhibited. PAG and RVM are major sites for opioid-induced analgesia. Apart from opioid receptors, the PAG and RVM also contain cannabinoid CB1 receptors \[[@B28-pharmaceuticals-03-02661],[@B29-pharmaceuticals-03-02661],[@B30-pharmaceuticals-03-02661]\]. Functional studies have shown that the microinjection of cannabinoids into the PAG and RVM produces antinociception to thermoceptive stimuli, reversed by selective cannabinoid CB1 receptor antagonists \[[@B33-pharmaceuticals-03-02661],[@B34-pharmaceuticals-03-02661],[@B42-pharmaceuticals-03-02661]\]. Even if intra-PAG cannabinoid-induced antinociception is relatively weaker than that one produced by opioids, opioid treatment results unsatisfactory due to a decrease of spinal opioid receptors whereas cannabinoid effectiveness is associated to an up-regulation of CB1 receptors in certain pathological conditions such as neuropathic pain \[[@B43-pharmaceuticals-03-02661],[@B44-pharmaceuticals-03-02661]\]. So far, the mostly used cannabinoid antagonists are the CB1 selective: SR141716A (rimonabant) and AM251 and the CB2 selective: SR144528 and AM630. SR141716A, AM251, SR144528 and AM630 are inverse agonists rather than ''pure'' or ''silent'' antagonists \[[@B45-pharmaceuticals-03-02661]\]. Moreover, AM630 behaves also as a weak partial inverse agonist at CB1 receptor \[[@B46-pharmaceuticals-03-02661]\] and AM251 might have antagonist/inverse agonist actions at GPR55 \[[@B47-pharmaceuticals-03-02661],[@B48-pharmaceuticals-03-02661]\]. Microinjection of a non selective CB1/CB2 receptor agonist, WIN 55,212-2, into the PAG produces an antinociceptive effect which proved to be dependent upon group I metabotropic glutamate subtype 5 (mGlu5) and group II and group III receptor stimulation. Indeed, apart from SR141716A, the effect of WIN55,212-2 was prevented by MPEP (a selective mGlu5 receptor antagonist), ethyl-glutamic acid (a selective group II mGlu receptor antagonist) and MSOP (a selective group III mGlu receptor antagonist) \[[@B49-pharmaceuticals-03-02661]\]. Pretreatment with a selective antagonist of *N*-methyl-D-aspartate (NMDA) receptors, DL-AP5, blocked the effect of WIN 55,212-2. This evidence suggests that physiological stimulation of mGlu and NMDA receptors is required to produce cannabinoid-induced analgesia in the PAG. In particular, pharmacological blockade of postsynaptic mGlu5 and NMDA receptors might reduce the tonic excitatory control of glutamate on antinociceptive pathways originating from the PAG. The effect of group II and III mGlu receptor antagonists could be mediated by increased GABAergic activity. Thus cannabinoid-induced antinociception, which necessitates of glutamate-induced PAG activation, would be prevented if NMDA, group I and group II and III metabotropic glutamate receptors are blocked. The first clarification of cellular mechanisms of cannabinoid-induced analgesia within the PAG and RVM came from Vaughan *et al.* \[[@B50-pharmaceuticals-03-02661],[@B51-pharmaceuticals-03-02661]\]. Tetrahydrocannabinol (THC), WIN 55,212-2 and HU-210 inhibited electrically-evoked and spontaneous miniature GABA~A~ mediated inhibitory postsynaptic currents (IPSCs) in PAG and RVM neurons. The cannabinoid-induced inhibition of synaptic transmission proved to be mediated by cannabinoid CB1 receptors since it was reversed by SR141716A and AM251, while not by SR144528 or the opioid receptor antagonist naloxone. Cannabinoids therefore inhibit GABAergic synaptic transmission on identified PAG and RVM output neurons and in doing so are thought to produce analgesia by reducing GABAergic inhibition of output neurons that form part of a descending analgesic pathway \[[@B52-pharmaceuticals-03-02661]\]. A functional interaction between PAG cannabinoid and mGlu receptors has subsequently been found in the modulation of pain responses monitored simultaneously to the neuronal activities of RVM nociceptive ON- and antinociceptive OFF- cells \[[@B53-pharmaceuticals-03-02661]\]. These RVM cell populations are characterized by opposite responses to pain stimuli: a burst of activity immediately prior to withdrawal reflexes (ON-cells) or an inhibition of activity immediately prior to withdrawal reflexes (OFF-cells) in the tail flick test \[[@B54-pharmaceuticals-03-02661]\]. These cells represent an electrophysiological approach for studying centrally acting analgesics. Intra-PAG microinjection of WIN 55,212-2 prevented formalin-induced changes in RVM cell activities and at higher doses, increased the tail flick latencies. WIN 55,212-2 also reduced the tail flick-related onset of the ON-cell burst as well as the duration of the OFF-cell pause. WIN 55,212-2 reduced and enhanced the ongoing activities of the ON- and OFF-cells, respectively. Such effects were prevented by either SR141716A, or by the selective mGlu5 receptor antagonist, MPEP. Conversely, the selective mGlu1 receptor antagonists, CPCCOEt and (*S*)-(+)-α-amino-4-carboxy-2-methylbenzeneacetic acid (LY367385), were ineffective in preventing WIN 55,212-2-induced effects. This study confirms that physiological stimulation of PAG mGlu5, although not of mGlu1 receptors, would appear to be required for the cannabinoid---induced changes in ongoing and pain-related changes (formalin and tail flick) in RVM ON- and OFF-cell activities \[[@B53-pharmaceuticals-03-02661]\]. A recent study has demonstrated that spillover of synaptically released glutamate, as a result of stress or pain, stimulates mGlu5 receptor inducing endocannabinoid release, which in turn activates presynaptic cannabinoid CB1 receptor. CB1 receptor activation reduces GABAergic tone thus dis-inhibiting the antinociceptive descending pathway. By this subject the neuronal glutamate transporter limits this heterosynaptic endocannabinoid-mediated cross-talk between glutamatergic and GABAergic synapses within the PAG. Neuronal glutamate transporters is likely to play an important role in regulating the endocannabinoid-mediated analgesic functions of the PAG \[[@B55-pharmaceuticals-03-02661]\]. A recent study by Drew *et al.* has shown that substance P may facilitate descending analgesia in part by enhancing glutamate-mediated excitation and endocannabinoid-mediated disinhibition of PAG-RVM projection neurons, this latter through inhibition of GABAergic transmission. Consistently with a role for endogenous glutamate in this process, this effect was prevented by mGlu5 receptor antagonist \[[@B56-pharmaceuticals-03-02661]\].

Several studies have demonstrated that stimulation of group I mGlu receptors promotes the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG), but not that of anandamide, via Gq/11 protein-activation and PLC-β-mediated cleavage of membrane phosphoinositides, which yields 1,2-diacylglycerol (1,2-DAG), followed by diacylglycerol lipase (DGL)-catalyzed conversion of 1,2-DAG to 2-AG \[[@B57-pharmaceuticals-03-02661],[@B58-pharmaceuticals-03-02661],[@B59-pharmaceuticals-03-02661]\] mechanism. Endocannabinoids may be released in this way from postsynaptic neurons, diffuse across the synaptic cleft and bind to CB1 receptors on presynaptic terminals to regulate calcium and potassium channel activities and ensuing neurotransmitter release \[[@B60-pharmaceuticals-03-02661],[@B61-pharmaceuticals-03-02661]\]. This retrograde signaling process seems to be widespread \[[@B62-pharmaceuticals-03-02661]\] in a variety of regions of the brain, including the striatum \[[@B62-pharmaceuticals-03-02661]\], hippocampus \[[@B63-pharmaceuticals-03-02661],[@B64-pharmaceuticals-03-02661],[@B65-pharmaceuticals-03-02661],[@B66-pharmaceuticals-03-02661],[@B67-pharmaceuticals-03-02661],[@B68-pharmaceuticals-03-02661]\], midbrain \[[@B69-pharmaceuticals-03-02661]\], and amygdala \[[@B70-pharmaceuticals-03-02661],[@B71-pharmaceuticals-03-02661]\]. On this subject, the reciprocal interactions between cannabinoid and metabotropic glutamate receptors may converge into a unique synaptical mechanism and could have relevant implications such as their simultaneous manipulation to produce analgesia.

4. Endocannabinoids within the Antinociceptive Descending Pathway
=================================================================

Electrical stimulation of the dorsal and lateral PAG produces analgesia that is unresponsive to blockade by opioid antagonists \[[@B72-pharmaceuticals-03-02661]\], is mediated by endocannabinoids, and blocked by CB1 receptor antagonists. Moreover, such electrical stimulation of the dorsal and lateral PAG resulted in anandamide mobilization and CB1 receptor -mediated analgesia \[[@B73-pharmaceuticals-03-02661]\]. It has been recently shown that 2-AG and anandamide are elevated in dorsal PAG concomitantly with non-opioid stress-induced analgesia (SIA) expression \[[@B74-pharmaceuticals-03-02661]\]. Moreover, microinjections within the PAG and RVM of inhibitors of fatty acid amide hydrolase (FAAH), the enzyme responsible of anandamide hydrolysis, such as URB597 \[[@B74-pharmaceuticals-03-02661]\] and arachidonoylserotonin (AA-5-HT) \[[@B75-pharmaceuticals-03-02661]\] enhanced SIA. Microinjection into the PAG of an inhibitor of the monoacylglycerol lipase, MGL, also induced enhancement of stress-induced antinociception which was CB1 receptor-dependent and associated with elevated levels of 2-AG (but not of anandamide). Apart from CB1 receptors, anandamide also stimulates a transient receptor potential vanilloid type 1 receptor (TRPV1). The effect of FAAH inhibitors may therefore be also due to this "alternative" endocannabinoid receptor involvement. In one of our recent studies, microinjections of URB597 into the ventrolateral PAG, by elevating both anandamide and 2-AG, induced a biphasic effect on thermal nociception and RVM ON and OFF cell activity via preferential CB1 and TRPV1 receptor activation. Throughout a set of pharmacological manipulation it has been determined that TRPV1 stimulation led to antinociception, whilst a low dose of URB597 facilitated nociception via CB1 stimulation (blocked by AM251) \[[@B75-pharmaceuticals-03-02661]\]. This effect was associated with enhanced or reduced activity of RVM OFF cells, suggesting that these effects occur via stimulation or inhibition of excitatory PAG output neurons, respectively. However, the highest doses of URB597 or WIN 55,212-2, caused only CB1-mediated analgesia associated with disinhibition of RVM OFF and inhibition of ON cells. Within ventrolateral PAG several neurons were found coexpressing TRPV1 and CB1 receptors. The study underlines bidiretional endocannabinoid control within the antinociceptive descending pathway, which through TRPV1 or CB1 receptor stimulation may differentially modulate pain perception \[[@B75-pharmaceuticals-03-02661]\].

Encannabinoid tone may be modified under certain pathological conditions such as chronic pain. The development of a sensitive method for measuring cannabinoids by atmospheric pressure-chemical ionization mass spectrometry, associated with microdialysis, has made it possible to show that electrical stimulation of the dorsal and lateral PAG produces CB1 receptor-mediated analgesia, accompanied by a marked increase in the release of anandamide. Furthermore, pain triggered by subcutaneous injections of the chemical irritant formalin substantially increased the release of anandamide in the PAG. These findings indicate that the endogenous cannabinoids, such as anandamide, play an important role in a cannabinergic pain-suppression system existing within the dorsal and lateral PAG \[[@B73-pharmaceuticals-03-02661]\]. Recent studies have shown that levels of anandamide and 2-AG, as well as those of the analgesic anandamide congener, palmitoylethanolamide (PEA), increased in three brain areas of the descending antinociceptive system, i.e. the dorsal raphe (DR), PAG and RVM, as well as in the spinal cord (SC) following chronic constriction injury (CCI) of the sciatic nerve in the rat \[[@B76-pharmaceuticals-03-02661]\]. Anandamide and 2-AG operating at both spinal and supra-spinal levels are therefore up-regulated during neuropathic pain and it is possible that substances that inhibit both endocannabinoid and PEA inactivation might be useful in the treatment of neuropathic pain. It has also been demonstrated that in neuropathic pain conditions the endocannabinoid and serotonergic systems proved hyperactive in the DR. Repeated stimulation of CB1 receptors with exogenous compounds restores DR serotonergic activity, as well as thermal and mechanical nociceptive thresholds to normal conditions \[[@B77-pharmaceuticals-03-02661]\]. Normalization of pain-induced over-activation of DR extracellular 5-HT by exogenous cannabinoids opens up the perspective that cannabinoid treatment could also resolve the negative emotional consequences of neuropathic pain, thus representing a possible and very promising advance in the clinical management of this highly debilitating condition.

5. The Development of Novel Analgesic Agents Targeting both Fatty Acid Amide Hydrolase and TRPV1 Receptors
==========================================================================================================

Compounds targeting more than one biological process may be more effective or provide a better safety profile than compounds that are selective on a unique target. Arachidonoylserotonin (AA-5-HT) is a "hybrid" compound with a dual function. It is an FAAH inhibitor \[[@B78-pharmaceuticals-03-02661]\] which has been shown to increase both peripheral and central AEA levels *in vivo* \[[@B79-pharmaceuticals-03-02661],[@B80-pharmaceuticals-03-02661]\] and whose actions proved to be blocked by a CB1 receptor antagonist/inverse agonists \[[@B75-pharmaceuticals-03-02661],[@B81-pharmaceuticals-03-02661]\]. AA-5-HT is also a potent (mid-nanomolar) antagonist of TRPV1 receptors expressed in HEK-293 cells \[[@B75-pharmaceuticals-03-02661]\], and this could contribute to the efficacy of the compound in models of both inflammatory (rat) and neuropathic pain (anti-allodynic effect, rat) \[[@B75-pharmaceuticals-03-02661]\]. The effects of AA-5-HT were examined after its administration intra-PAG. As expected, AA-5-HT increased endocannabinoid levels in the PAG and induced analgesia. It depressed the RVM ON cell activities as well as those of the OFF cells. The effect of AA-5-HT was mimicked by co-injecting URB597 (a selective FAAH inhibitor) and I-RTX (the selective TRPV1 antagonisint). This drug combination also produced analgesia associated with an inhibition of ongoing ON and OFF cell activities. It has been suggested that the recruitment of "alternative" pathways, such as PAG-locus coeruleus (LC)-spinal cord might be responsible for the AA-5-HT effect \[[@B82-pharmaceuticals-03-02661]\]. Evidence that intra-PAG AA-5-HT increased LC neuron firing activities and intrathecal phentolamine or ketanserin prevented the analgesic effect of AA-5-HT indeed confirmed this hypothesis. Intra-PAG AA-5-HT also prevented the changes in the firing activity of ON and OFF cells induced by formalin intra-paw, and it inverted the formalin-induced increase in LC adrenergic cell activity. All AA-5-HT effects were antagonized by cannabinoid CB1 and TRPV1 receptor antagonists, thus suggesting that co-localization of these receptors in the PAG could be an appropriate neural substrate for AA-5-HT-induced analgesia \[[@B82-pharmaceuticals-03-02661]\].

6. Conclusions
==============

The ability of cannabinoids to induce antinociception in every animal model has encouraged researchers to gain a greater understanding of this non-opioid analgesic system. Neuroanatomical and site-specific pharmacological studies have revealed the presence of CB1, endocannabinoids and endocannabinoid-degrading enzymes at supraspinal level and in particular within the PAG*-*RVM system, which has been the focus of many pain studies in recent years. Within this circuitry cannabinoids produce analgesia through the dis-inhibition of PAG glutamatergic projecting neurons that results in the stimulation of RVM OFF cells and inhibition of the ON cells. Cannabinoid agonists and FAAH inhibitors of at this level have proved to be analgesics. Moreover, novel compounds with a dual target, such as FAAH inhibition and TRPV1 receptor blockade, may cause analgesic effects that are stronger than they would be if acting on each single target, individually, due to the different respective roles and mechanisms of action in the control of nociception,. With respect to this, hybrid compounds acting on dual targets may prove to be effective where "classic" analgesics have failed. Greater understanding of the cannabinoid mechanisms of action underlying PAG-RVM-induced analgesia could be a step forward in the search for alternative pathological pain treatment.
